Fresenius Ventures

Latest fund size

$228M

Announced

July 24, 2026

Global HQ

Germany

Members only

Check size

$5M-$20M

Members only

Stage focus

Seed, Series A, Series B, Growth (Series C+)

Members only

Regions of investment

Europe

Members only

About

Fresenius Ventures is the corporate venture capital (CVC) arm of Fresenius SE & Co. KGaA, a Bad Homburg, Germany-based global healthcare company. Launched in July 2026, the unit combines venture investing with Fresenius' medical, regulatory, and operational expertise, and connects portfolio companies to clinical, scientific, and academic networks.

Contact info

Members only

Names, roles, emails and LinkedIn profiles for the team, plus the fund's website.

Investment focus

Fresenius Ventures invests in healthcare founders, technologies, and business models from early financing rounds through the growth stage, in growth fields adjacent to Fresenius' existing strategic platforms: BioPharma, MedTech, and Care Provision.

Potential investment areas include precision nutrition, microbiome research, new treatment modalities, and digital care provision solutions.

Members only

What the fund looks for in founders and which sectors it backs.

Fund

Fresenius Ventures is a corporate venture capital (CVC) fund, not an LP-raised fund, it is capitalized directly by parent company Fresenius SE & Co. KGaA rather than through a traditional fundraise or first close.

The unit has an intended investment volume of more than $228M (≈€200M) to be deployed over the next five years, in line with Fresenius' capital allocation approach.

Members only

Fund size, LPs and track record.

Other information

Leadership

Dr. Thomas Michael Thestrup is Managing Director and Head of Fresenius Ventures.

He joined from Angelini Ventures, the corporate venture arm of Italian industrial group Angelini Industries, and previously held roles at Lundbeck A/S (Director of Corporate Business Development and Strategy), UCB (Global Business Development), and Sunstone Capital (Life Science Ventures).

He holds a Ph.D. from the Max Planck Institute of Neurobiology in Munich. Michael Sen serves as CEO of parent company Fresenius.

‍

Investment Strategy

Fresenius Ventures combines capital with medical, regulatory, and operational expertise, and connects portfolio companies to clinical, scientific, and academic networks.

The unit invests across the financing lifecycle, from early rounds through growth-stage.

Members only

Leadership, investment strategy, notable investments and exits.

Unlock this fund's full profile

✓ Emails and LinkedIn for the team

✓ Check size, stage focus and regions of investment

✓ LPs, notable investments and exits

✓ Search and filters across 700+ funds

Unlock this fund and 700+ more

From $14/month, billed yearly. Cancel any time.

Read the newsletter that top VCs and founders keep in their inbox.

Join the weekly newsletter